Nanoparticle-assisted combination therapies for effective cancer treatment

Therapeutic Delivery

Volumn 1, Issue 2, 2010, Pages 323-334

  Hu, Che Ming Jack ^a   Aryal, Santosh ^a   Zhang, Liangfang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; COMBRETASTATIN; CPX 1; CPX 351; CPX 571; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DENDRIMER; DOCETAXEL; DOXORUBICIN; FLOXURIDINE; IRINOTECAN; LIPOSOME; MACROGOL; MERCAPTOPURINE; NANOPARTICLE; OLIGONUCLEOTIDE; POLYCAPROLACTONE; POLYGLACTIN; POLYMER; QUERCETIN; SMALL INTERFERING RNA; TRANSFERRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CONTROLLED DRUG RELEASE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COATING; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DOSAGE FORM COMPARISON; DRUG MANUFACTURE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; LEWIS CARCINOMA; LIPOSOMAL DELIVERY; LUNG CARCINOMA; LUNG SMALL CELL CANCER; MELANOMA; MONOTHERAPY; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 78650317418     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.10.13     Document Type: Review

References (78)

1. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771-782 (2008).
2. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83(5), 761-769 (2008). (Pubitemid 351556021)
3. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751-760 (2007). (Pubitemid 350223348)
4. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46(12 Pt 1), 6387-6392 (1986). (Pubitemid 17221789)
5. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56(11), 1649-1659 (2004). (Pubitemid 39177694)
6. Northfelt DW, Dezube BJ, Thommes JA et al. PEGylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol. 16(7), 2445-2451 (1998). (Pubitemid 28309039)
7. Harries M, Ellis P, Harper P. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. J. Clin. Oncol. 23(31), 7768-7771 (2005). (Pubitemid 46657369)
8. Gottesman MM. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53, 615-627 (2002). (Pubitemid 34177898)
9. Lehar J, Krueger AS, Avery W et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27(7), 659-666 (2009).
10. Greco F, Vicent MJ. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 61(13), 1203-1213 (2009).
11. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13(1), 238-252 (1965).
12. Johnson SM, Bangham AD, Hill MW, Korn ED. Single bilayer liposomes. Biochim. Biophys. Acta. 233(3), 820-826 (1971).
13. Olson F, Hunt CA, Szoka FC, Vail WJ, Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim. Biophys. Acta. 557(1), 9-23 (1979). (Pubitemid 10245657)
14. Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 23(7), 1417-1450 (2006). (Pubitemid 43993807)
15. Hubert A, Lyass O, Pode D, Gabizon A. Doxil™ (Caelyx™): an exploratory study with pharmacokinetics in patients with hormonerefractory prostate cancer. Anticancer Drugs 11(2), 123-127 (2000). (Pubitemid 30193068)
16. Judson I, Radford JA, Harris M et al. Randomised Phase II trial of pegylated liposomal doxorubicin (Doxil™/Caelyx™) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer 37(7), 870-877 (2001). (Pubitemid 32323965)
17. Guaglianone P, Chan K, DelaFlor-Weiss E et al. Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome™). Invest. New Drugs 12(2),103-110 (1994). (Pubitemid 24350647)
18. Forssen EA, Male-Brune R, Adler-Moore JP et al. Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome™) within tumor tissue. Cancer Res. 56(9), 2066-2075 (1996). (Pubitemid 26119909)
19. Jaeckle KA, Batchelor T, O'Day SJ et al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J. Neurooncol. 57(3), 231-239 (2002). (Pubitemid 34692631)
20. Glantz MJ, Jaeckle KA, Chamberlain MC et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 5(11), 3394-3402 (1999).
21. Anonymous. Vincristine liposomal-INEX: lipid-encapsulated vincristine, onco TCS, transmembrane carrier system-vincristine, vincacine, vincristine sulfate liposomes for injection, VSLI. Drugs R. D. 5(2), 119-123 (2004).
22. Zhang L, Pornpattananangku D, Hu CM, Huang CM. Development of nanoparticles for antimicrobial drug delivery. Curr. Med. Chem. 17(6), 585-594 (2009).
23. Agrawal V, Paul MK, Mukhopadhyay AK. 6-mercaptopurine and daunorubicin double drug liposomes-preparation, drug-drug interaction and characterization. J. Liposome Res. 15(3-4), 141-155 (2005). (Pubitemid 43062263)
24. Nelson JA, Carpenter JW, Rose LM, Adamson DJ. Mechanisms of action of 6-thioguanine, 6-mercaptopurine and 8-azaguanine. Cancer Res. 35(10), 2872-2878 (1975).
25. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, Johnstone SA et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol. Cancer Ther. 5(7), 1854-1863 (2006). (Pubitemid 44323254)
26. Pavillard V, Kherfellah D, Richard S, Robert J, Montaudon D. Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants. Br. J. Cancer 85(7), 1077-1083 (2001). (Pubitemid 33016012)
27. Johnston JS, Johnson A, Gan Y, Wientjes MG, Au JL. Synergy between 3'-azido-3'-deoxythymidine and paclitaxel in human pharynx FaDu cells. Pharm. Res. 20(7),957-961 (2003). (Pubitemid 36774264)
28. Aung TT, Davis MA, Ensminger WD, Lawrence TS. Interaction between gemcitabine and mitomycin-C in vitro. Cancer Chemother. Pharmacol. 45(1), 38-42 (2000). (Pubitemid 30099713)
29. Tardi P, Johnstone S, Harasym N et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk. Res. 33(1),129-139 (2009).
30. Harasym TO, Tardi PG, Harasym NL, Harvie P, Johnstone SA, Mayer LD. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. Oncol. Res. 16(8), 361-374 (2007). (Pubitemid 47413252)
31. Hu CM, Zhang L. Therapeutic nanoparticles to combat cancer drug resistance. Curr. Drug. Metab. 10, 836-841 (2009).
32. Wu J, Lu Y, Lee A et al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 10(3), 350-357 (2007). (Pubitemid 350065179)
33. Mross K, Hamm K, Hossfeld DK. Effects of verapamil on the pharmacokinetics and metabolism of epirubicin. Cancer Chemother. Pharmacol. 31(5), 369-375 (1993). (Pubitemid 23045649)
34. Pennock GD, Dalton WS, Roeske WR et al. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J. Natl Cancer Inst. 83(2), 105-110 (1991).
35. Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine 3(6), 761-776 (2008).
36. Zhang L, Radovic-Moreno AF, Alexis F, Gu FX, Basto PA, Bagalkot V et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2(9), 1268-1271 (2007).
37. Aryal S, Hu CM, Zhang L. Polymer- cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano 4(1), 251-258 (2010).
38. Putnam D, Kopecek J. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122, 55-123 (1995).
39. Takakura Y, Hashida M. Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Crit. Rev. Oncol. Hematol. 18(3), 207-231 (1995).
40. Kratz F, Beyer U, Schutte MT. Drug- polymer conjugates containing acidcleavable bonds. Crit. Rev. Ther. Drug Carrier Syst. 16(3), 245-288 (1999). (Pubitemid 29305204)
41. Roth T, Kratz F, Steidle C, Unger C, Fiebig HH. In vitro and in vivo antitumor efficacy of acid albumin and poly(ethylene) glycol conjugates of doxorubicine. Ann. Oncol. 9, 102 (1998).
42. Bazile D, Prud'homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M. Stealth Me. PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 84(4), 493-498 (1995).
43. Allemann E, Brasseur N, Benrezzak O et al. PEG-coated poly(lactic acid) nanoparticles for the delivery of hexadecafluoro zinc phthalocyanine to EMT-6 mouse mammary tumours. J. Pharm. Pharmacol. 47(5), 382-387 (1995).
44. Sengupta S, Eavarone D, Capila I et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436(7050), 568-572 (2005). (Pubitemid 41112931)
45. Lammers T, Subr V, Ulbrich K et al. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 30(20), 3466-3475 (2009).
46. Abeylath SC, Turos E, Dickey S, Lim DV. Glyconanobiotics: Novel carbohydrated nanoparticle antibiotics for MRSA and Bacillus anthracis. Bioorg. Med. Chem. 16(5), 2412-2418 (2008). (Pubitemid 351403660)
47. Song XR, Cai Z, Zheng Y et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur. J. Pharm. Sci. 37(3-4), 300-305 (2009).
48. Soma CE, Dubernet C, Bentolila D, Benita S, Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 21(1), 1-7 (2000).
49. Adel AL, Dorr RT, Liddil JD. The effect of anticancer drug sequence in experimental combination chemotherapy. Cancer Invest. 11(1), 15-24 (1993). (Pubitemid 23041445)
50. Cao S, Rustum YM. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res. 60(14), 3717-3721 (2000). (Pubitemid 32204557)
51. Bae Y, Diezi TA, Zhao A, Kwon GS. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J. Control. Release 122(3), 324-330 (2007). (Pubitemid 47404677)
52. Tong R, Cheng J. Paclitaxel-initiated, controlled polymerization of lactide for the formulation of polymeric nanoparticulate delivery vehicles. Angew. Chem. Int. Ed. 47(26), 4830-4834 (2008).
53. Tong R, Cheng J. Ring-opening polymerization-mediated controlled formulation of polylactide-drug nanoparticles. J. Am. Chem. Soc. 131(13), 4744-4754 (2009).
54. Tong R, Tang L, Yala L, Cheng J. Controlled formulation of doxorubicin-polylactide nanoconjugates for cancer drug delivery. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2400-2402 (2009).
55. Tekade RK, Dutta T, Gajbhiye V, Jain NK. Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetics. J. Microencap. 26(4), 287-296 (2009).
56. Kaneshiro TL, Lu ZR. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials 30(29), 5660-5666 (2009).
57. Aryal S, Grailer JJ, Pilla S, Steeber DA, Gong SQ. Doxorubicin conjugated gold nanoparticles as water-soluble and pH-responsive anticancer drug nanocarriers. J. Mat. Chem. 19(42), 7879-7884 (2009).
58. Gibson JD, Khanal BP, Zubarev ER. Paclitaxel-functionalized gold nanoparticles. J. Am. Chem. Soc. 129(37), 11653-11661 (2007). (Pubitemid 47555582)
59. Hwu JR, Lin YS, Josephrajan T et al. Targeted paclitaxel by conjugation to iron oxide and gold nanoparticles. J. Am. Chem. Soc. 131(1),66-68 (2009).
60. Chen J, Chen S, Zhao X, Kuznetsova LV, Wong SS, Ojima I. Functionalized singlewalled carbon nanotubes as rationally designed vehicles for tumor-targeted drug delivery. J. Am. Chem. Soc. 130(49), 16778-16785 (2008).
61. Feazell RP, Nakayama-Ratchford N, Dai H, Lippard SJ. Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J. Am. Chem. Soc. 129(27), 8438-8439 (2007). (Pubitemid 47066504)
62. Chen AM, Zhang M, Wei D et al. Codelivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrugresistant cancer cells. Small 5(23), 2673-2677 (2009).
63. Journe F, Chaboteaux C, Laurent G, Body JJ. Sequence-dependent synergistic effects of ibandronate in combination with antiestrogens on growth inhibition of estrogen receptor-positive breast cancer cells. Bone 38(3), S52-S53 (2006).
64. Lu Z, Tsai M, Lu D, Wang J, Wientjes MG, Au JL. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer. J. Pharmacol. Exp. Ther. 327(3),673-682 (2008).
65. Lu D, Wientjes MG, Lu Z, Au JL. Tumor priming enhances delivery and efficacy of nanomedicines. J. Pharmacol. Exp. Ther. 322(1), 80-88 (2007). (Pubitemid 46956353)
66. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279(5349), 377-380 (1998). (Pubitemid 28063372)
67. Farokhzad OC, Cheng J, Teply BA et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA 103(16), 6315-6320 (2006).
68. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res. 62(24), 7190-7194 (2002). (Pubitemid 36025236)
69. Park JW, Kirpotin DB, Hong K et al. Tumor targeting using anti-her 2 immunoliposomes. J. Control. Release 74(1-3), 95-113 (2001). (Pubitemid 32727613)
70. Olafsen T, Tan GJ, Cheung CW et al. Characterization of engineered antip185HER- (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng. Des. Sel. 17(4), 315-323 (2004). (Pubitemid 39093511)
71. Leyton JV, Olafsen T, Sherman MA et al. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng. Des. Sel. 22(3), 209-216 (2009).
72. Batist G, Gelmon KA, Chi KN et al. Safety, pharmacokinetics and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin. Cancer Res. 15(2), 692-700 (2009).
73. Tardi PG, Dos Santos N, Harasym TO et al. Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol. Cancer Ther. 8(8), 2266-2275 (2009).
74. Wong MY, Chiu GN. Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment. Anticancer Drugs 21(4), 401-410 (2010).
75. Wang Y, Gao S, Ye WH, Yoon HS, Yang YY. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mater. 5(10), 791-796 (2006). (Pubitemid 44570860)
76. Zhu C, Jung S, Luo S et al. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials 31(8), 2408-2416.
77. Tekade RK, Dutta T, Tyagi A et al. Surface-engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy. J. Drug Target 16(10), 758-772 (2008).
78. Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm. 6(3), 928-939 (2009).